[1] |
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447.
doi: 10.1182/blood-2016-08-733196
URL
|
[2] |
Schuettengruber B, Bourbon HM, Di Croce L, et al. Genome regulation by polycomb and trithorax: 70 years and counting[J]. Cell, 2017, 171(1): 34-57.
doi: S0092-8674(17)30890-5
pmid: 28938122
|
[3] |
Fujino T, Kitamura T. ASXL1 mutation in clonal hematopoiesis[J]. Exp Hematol, 2020, 83: 74-84.
doi: 10.1016/j.exphem.2020.01.002
URL
|
[4] |
Inoue D, Fujino T, Sheridan P, et al. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies[J]. Leukemia, 2018, 32(6): 1327-1337.
doi: 10.1038/s41375-018-0083-3
URL
|
[5] |
Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB[J]. Nature, 2010, 465(7295): 243-247.
doi: 10.1038/nature08966
URL
|
[6] |
Hsu YC, Chiu YC, Lin CC, et al. The distinct biological implications of ASXL1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model[J]. J Hematol Oncol, 2017, 10(1): 1-15.
doi: 10.1186/s13045-016-0379-6
URL
|
[7] |
Zhang P, Chen Z, Li R, et al. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates[J]. Cell Discov, 2018, 4: 4.
doi: 10.1038/s41421-017-0004-z
pmid: 29423272
|
[8] |
周柰岑, 李国辉, 秦炜炜, 等. 伴ASXL1基因突变的急性髓系白血病患者的临床特征及预后分析[J]. 中国实验血液学杂志, 2021, 29(6):1741-1745.
|
[9] |
Kakosaiou K, Panitsas F, Daraki A, et al. ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics[J]. Leuk Lymphoma, 2018, 59(10): 2439-2446.
doi: 10.1080/10428194.2018.1433298
URL
|
[10] |
Kitamura T. ASXL1 mutations gain a function[J]. Blood, 2018, 131(3): 274-275.
doi: 10.1182/blood-2017-12-816595
pmid: 29348310
|
[11] |
Prats-Martín C, Burillo-Sanz S, Morales-Camacho RM, et al. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype[J]. Cancer Med, 2020, 9(11): 3637-3646.
doi: 10.1002/cam4.2947
URL
|
[12] |
林云. 伴ASXL1基因突变成人初诊急性髓系白血病的临床特征及预后研究[D]. 福建医科大学, 2016.
|
[13] |
Alvarez Argote J, Dasanu CA. ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival[J]. Curr Med Res Opin, 2018, 34(5): 757-763.
doi: 10.1080/03007995.2016.1276896
URL
|
[14] |
Liu F, Gong M, Gao L, et al. RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia[J]. Onco Targets Ther, 2017, 10: 4143-4151.
doi: 10.2147/OTT.S142528
URL
|
[15] |
Devillier R, Mansat-De Mas V, Gelsi-Boyer V, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes[J]. Oncotarget, 2015, 6(10): 8388-8396.
doi: 10.18632/oncotarget.3460
pmid: 25860933
|
[16] |
滕广帅, 王颖韶, 徐晶, 等. ASXL1突变的髓系肿瘤患者共突变基因谱及其临床意义[J]. 天津医药, 2018, 46(12): 1295-1299.
|
[17] |
Makishima H. Somatic SETBP1 mutations in myeloid neoplasms[J]. Int J Hematol, 2017, 105(6): 732-742.
doi: 10.1007/s12185-017-2241-1
pmid: 28447248
|
[18] |
王双玲, 林建雄, 刘峰, 等. TET2在急性髓系白血病中的突变情况及其临床特征[J]. 中国实用医药, 2019, 14(31): 1-3.
|
[19] |
Bera R, Chiu MC, Huang YJ, et al. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia[J]. J Hematol Oncol, 2019, 12(1): 104-122.
doi: 10.1186/s13045-019-0789-3
URL
|
[20] |
Nagase R, Inoue D, Pastore A, et al. Expression of mutant ASXL1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation[J]. J Exp Med, 2018, 215(6): 1729-1747.
doi: 10.1084/jem.20171151
URL
|
[21] |
Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias[J]. Leukemia, 2010, 24(2): 469-473.
doi: 10.1038/leu.2009.218
pmid: 19865112
|
[22] |
胡晋君.TET2(rs2454206、rs12498609)及ASXL1(rs3746609) 单核苷酸多态性与MDS及其向AML转化的相关性研究[D]. 山西医科大学,2019.
|